Please login to the form below

Not currently logged in
Email:
Password:

Iris Pauporté joins OSE Immunotherapeutics

She becomes clinical project director at the French biotech

OSE Immunotherapeutics Iris PauportéNantes, France-based biotech OSE Immunotherapeutics has bolstered its clinical team with the appointment of Iris Pauporté as clinical project director.

Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential in other cancer indications.

She brings over 20 years of biomedical and clinical research experience to the team, and joins from the French National Cancer Institute (INCa) where she supervised the insitute's breast cancer research programme.

Prior to this, Pauporté worked for the UNICANCER hospital group as a project leader overseeing both clinical research and regulatory affairs. She also brings experience as a research coordinator at Takeda Laboratories, where she served between 1997 and 2004.

Alain Chatelin, medical director at OSE Immunotherapeutics, said: “We are very pleased to have Iris join our team.

“She brings significant expertise in clinical research and a network of opinion leaders in oncology and immuno-oncology.”

28th September 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics